2 active not recruiting, 2 completed, 2 withdrawn, 1 recruiting. 7 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 2, Active not recruiting 1, Recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 4 | Active not recruiting 2, Withdrawn 2 |
Follow Platinum-Refractory Ovarian Carcinoma: new trials by email Literature Review of Platinum-Refractory Ovarian Carcinoma trials Research Report on Platinum-Refractory Ovarian Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer Bevacizumab, Biospecimen Collection, Computed Tomography - Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2025-10-31 | 2025-06-03 | |
| A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors NKT3964, Paclitaxel, Doxorubicin - Solid Tumor, Advanced Solid Tumor | Phase 1 | Recruiting | NiKang Therapeutics, Inc. | 238 | 2024-09-19 | 2026-11-05 |
| A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors NKT3447 - Solid Tumor, Solid Tumor, Adult | Phase 1 | Terminated | NiKang Therapeutics, Inc. | 23 | 2024-02-23 | 2025-09-25 |
| Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy Computed Tomography, Copanlisib Hydrochloride, Magnetic Resonance Imaging - Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2022-06-30 | 2023-09-26 | |
| Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. TILT-123, pembrolizumab, pegylated liposomal doxorubicin - Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer | Phase 1 / Phase 2 | Active not recruiting | TILT Biotherapeutics Ltd. | 29 | 2022-05-17 | 2026-05-05 |
| Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents Biospecimen Collection, Cediranib Maleate, Computed Tomography - Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 120 | 2021-06-10 | 2026-10-22 |
| Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial) PHI-101 administration - Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma | Phase 1 | Unknown | Seoul National University Hospital | 36 | 2020-12-17 | 2023-06-26 |
| Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Malignant Peritoneal Neoplasm, Malignant Retroperitoneal Neoplasm | Phase 1 | Completed | M.D. Anderson Cancer Center | 26 | 2018-09-21 | 2025-05-22 |
| Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors Nintedanib, Bevacizumab - Renal Cell Carcinoma, Colorectal Adenocarcinoma | Phase 1 | Completed | University of Alabama at Birmingham | 21 | 2016-06-09 | 2018-07-10 |
Endometrial Neoplasms (3) · Ovarian Neoplasms (3) · Neoplasm Metastasis (2) · Small Cell Lung Carcinoma (2) · Stomach Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Uterine Cervical Neoplasms (2) · Uterine Diseases (2) · Adenoviridae Infections (1) · Carcinoma, Renal Cell (1) · Fallopian Tube Neoplasms (1) · Peritoneal Neoplasms (1)
Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Genital Diseases (4) · Genital Diseases, Female (4) · Genital Neoplasms, Female (4) · Neoplasms (4) · Neoplasms by Site (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4) · Uterine Neoplasms (4) · Adnexal Diseases (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3)
Paclitaxel (4) · Doxorubicin (3) · Magnetic Resonance Spectroscopy (3) · Taxes (3) · liposomal doxorubicin (3) · Bevacizumab (2) · Disulfides (2) · Immunoglobulin G (2) · Specimen Handling (2) · Topotecan (2) · olaparib (2) · 1-dodecylpyridoxal (1) · ASTX-660 (1) · CTLA-4 Antigen (1) · Contrast Media (1)
National Cancer Institute (NCI) (3) · NiKang Therapeutics, Inc. (2) · M.D. Anderson Cancer Center (1) · Seoul National University Hospital (1) · TILT Biotherapeutics Ltd. (1) · University of Alabama at Birmingham (1)
United States (7) · South Korea (2) · Finland (1) · Puerto Rico (1)
Amir A Jazaeri (1) · Francisco Robert, MD (1) · Hee Seung Kim, MD (1) · Jung-min Lee (1) · Kristen P Zeligs (1) · Panagiotis A Konstantinopoulos (1)
PMID 30603797, PMID 34980026, PMID 38471508, PMID 39506856, PMID 41566775
U10CA180868 (3)